Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells. Issue 17 (15th September 2018)
- Record Type:
- Journal Article
- Title:
- Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells. Issue 17 (15th September 2018)
- Main Title:
- Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells
- Authors:
- Huang, Yaping
Sun, Geng
Wang, Pengfei
Shi, Rui
Zhang, Yanchun
Wen, Xiaoan
Sun, Hongbin
Chen, Caiping - Abstract:
- Graphical abstract: In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I. Highlights: First report on anticancer activity of Complex I inhibitor R419 . Twenty R419 derivatives were synthesized. H20 is the most potent compound against HepG2 cells. H20 caused cellular ATP depletion and necrosis. H20 displayed inhibitory activity against Complex I. Abstract: In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death.Graphical abstract: In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I. Highlights: First report on anticancer activity of Complex I inhibitor R419 . Twenty R419 derivatives were synthesized. H20 is the most potent compound against HepG2 cells. H20 caused cellular ATP depletion and necrosis. H20 displayed inhibitory activity against Complex I. Abstract: In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I. … (more)
- Is Part Of:
- Bioorganic & medicinal chemistry letters. Volume 28:Issue 17(2018)
- Journal:
- Bioorganic & medicinal chemistry letters
- Issue:
- Volume 28:Issue 17(2018)
- Issue Display:
- Volume 28, Issue 17 (2018)
- Year:
- 2018
- Volume:
- 28
- Issue:
- 17
- Issue Sort Value:
- 2018-0028-0017-0000
- Page Start:
- 2957
- Page End:
- 2960
- Publication Date:
- 2018-09-15
- Subjects:
- Complex I -- R419 -- Flavonoids derivatives -- Human hepatocellular carcinoma
Bioorganic chemistry -- Periodicals
Pharmaceutical chemistry -- Periodicals
572 - Journal URLs:
- http://www.elsevier.com/wps/find/journaldescription.cws_home/972/description#description ↗
http://www.sciencedirect.com/science/journal/0960894X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.bmcl.2018.07.006 ↗
- Languages:
- English
- ISSNs:
- 0960-894X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.330000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20835.xml